06 Mar 2024

Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024

Therapeutics

19 Jan 2024

Appointment of Christina Coughlin, M.D., Ph.D. as Head of Research and Development

Investors | Therapeutics

19 Dec 2023

Appointment of Chief Business Officer

Investors | Therapeutics

13 Dec 2023

ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data

Investors | Therapeutics

04 Dec 2023

Shareholder update to review AVA6000 Phase 1a data

Investors | Therapeutics

15 Nov 2023

Affimer^® biotherapeutics: The next generation of cancer therapies

Blogs | Therapeutics

05 Oct 2023

Avacta to present promising new data from Affimer^® and pre|CISION^TM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Investors | Therapeutics

20 Sep 2023

Appointment of Dr. Christina Coughlin as a consultant

Investors | Therapeutics

19 Sep 2023

Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update

Investors | Therapeutics

21 Jun 2023

Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study

Investors | Therapeutics